CTS3497 / CytosinLab - LARVOL DELTA

First-in-human phase I study of CTS3497, a methylthioadenosine (MTA)-cooperative PRMT5 inhibitor, in patients with advanced/metastatic methylthioadenosine phosphorylase (MTAP)-deficient solid tumors and lymphomas (ESMO 2025) - P1/2 | "Legal entity responsible for the study CytosinLab Therapeutics Co., Ltd. Funding CytosinLab Therapeutics Co., Ltd."

Clinical • First-in-human • Metastases • P1 data • Biliary Cancer • Cholangiocarcinoma • Colorectal Cancer • Hematological Malignancies • Lung Cancer • Lymphoma • Malignant Pleural Mesothelioma • Mesothelioma • Non Small Cell Lung Cancer • Oncology • Pleural Mesothelioma • Solid Tumor • MTAP • PRMT5

A Phase I/II Clinical Study of CTS3497 in Patients With MTAP Deficient Malignacies (clinicaltrials.gov) - P1/2 | N=224 | Recruiting | Sponsor: CytosinLab Therapeutics Co., Ltd.

New P1/2 trial • Brain Cancer • Hematological Malignancies • Lung Cancer • Lymphoma • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Urothelial Cancer

Targeting arginine methylome in 9p21/MTAP-deleted malignant cancers with a next generation PRMT5-specific inhibitor CTS3497 (AACR 2024) - "Furthermore, a synergistic anti-tumor effect was observed in multiple MTAP-deleted tumors when combining PRMT5 inhibition with CTS2190, an investigational type-I PRMT inhibitor currently in phase I/II clinical trials. Its superior ADME properties and favorable safety profiles observed in preclinical studies mark a breakthrough in the next generation epigenetic therapy. CTS3497 emerges as a promising therapeutic option for patients with MTAP-deleted malignancies."

Brain Cancer • Lung Cancer • Oncology • Solid Tumor • MTAP